





PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

AGE: 34 Years SEX: Female

ABHA NO:

26/11/2022 13:39:00

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval

cause any signs or symptoms, so a cholesterol test is an important tool. High cholesterol levels often are a significant risk factor for heart disease and important for diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Serum Triglyceride are a type of fat in the blood. When you eat, your body converts any calories it doesn" t need into triglycerides, which are stored in fat cells. High triglyceride levels are associated with several factors, including being overweight, eating too many sweets or drinking too much alcohol, smoking, being sedentary, or having diabetes with elevated blood sugar levels. Analysis has proven useful in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism, and various endocrine disorders. In conjunction with high density lipoprotein and total serum cholesterol, a triglyceride determination provides valuable information for the assessment of coronary heart disease risk. It is done in fasting state.

High-density lipoprotein (HDL) cholesterol. This is sometimes called the ""good"" cholesterol because it helps carry away LDL cholesterol, thus keeping arteries open and blood flowing more freely.HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

SERUM LDL The small dense LDL test can be used to determine cardiovascular risk in individuals with metabolic syndrome or established/progressing coronary artery disease, individuals with triglyceride levels between 70 and 140 mg/dL, as well as individuals with a diet high in trans-fat or carbohydrates. Elevated sdLDL levels are associated with metabolic syndrome and an 'atherogenic lipoprotein profile', and are a strong, independent predictor of cardiovascular disease. Elevated levels of LDL arise from multiple sources. A major factor is sedentary lifestyle with a diet high in saturated fat. Insulin-resistance and pre-diabetes have also been implicated, as has genetic predisposition. Measurement of sdLDL allows the clinician to get a more comprehensive picture of lipid risk factors and tailor treatment accordingly. Reducing LDL levels will reduce the risk of CVD and MI.

Non HDL Cholesterol - Adult treatment panel ATP III suggested the addition of Non-HDL Cholesterol as an indicator of all atherogenic lipoproteins (mainly LDL and VLDL). NICE guidelines recommend Non-HDL Cholesterol measurement before initiating lipid lowering therapy. It has also been shown to be a better marker of risk in both primary and secondary prevention studies.

Recommendations:

Results of Lipids should always be interpreted in conjunction with the patient's medical history, clinical presentation and other findings.

NON FASTING LIPID PROFILE includes Total Cholesterol, HDL Cholesterol and calculated non-HDL Cholesterol. It does not include triglycerides and may be best used in patients for whom fasting is difficult.
GLUCOSE FASTING, FLUORIDE PLASMA-TEST DESCRIPTION

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in

Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortical insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin, ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents. NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and< 40 mg/dL in women.

Hypoglycemia is defined as a glucoseor < 50 mg/dL in men and< 40 mg/dL in women. While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1.Evaluating the long-term control of blood glucose concentrations in diabetic patients.

1.Evaluating the long-term control of blood glocals and provided in the language of the langua

eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

HbA1c Estimation can get affected due to:

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10. NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report

Page 14 Of 15

Patient Ref. No. 22000000811279







PATIENT NAME: MRS. MRS.YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO :

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

End Of Report Please visit www.srlworld.com for related Test Information for this accession

Dr.Akta Dubey

Counsultant Pathologist

Dr. Rekha Nair, MD

Microbiologist


SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,



Scan to View Details











PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005940

34 Years AGE:

SEX: Female

ABHA NO : REPORTED :

26/11/2022 15:52:19

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 26/11/2022 14:20:00

RECEIVED: 26/11/2022 14:20:11

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:5615822 REONO-1326189

CORP-OPD

BILLNO-1501220PCR059905

BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval

Units

BIO CHEMISTRY

GLUCOSE, POST-PRANDIAL, PLASMA


PPBS(POST PRANDIAL BLOOD SUGAR)

80

70 - 139

mg/dL

METHOD: HEXOKINASE



NOTE: - RECHECKED FOR POST PRANDIAL PLASMA GLUCOSE VALUES, TO BE CORRELATE WITH CLINICAL, DIETETIC AND THERAPEUTIC HISTORY.

Interpretation(s)
GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c

End Of Report Please visit www.srlworld.com for related Test Information for this accession

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details











PATIENT NAME: MRS. MRS.YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005940

AGE: 34 Years

SEX: Female

ABHA NO:

DRAWN: 26/11/2022 14:20:00

RECEIVED: 26/11/2022 14:20:11

REPORTED:

26/11/2022 15:52:19

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR:

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results


Biological Reference Interval

Units

Dr.Akta Dubey **Counsultant Pathologist**

SRL LtdHIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,







Scan to View Report









PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO:

REPORTED:

26/11/2022 19:53:33

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval

Units

SPECIALISED CHEMISTRY - HORMONE

THYROID PANEL, SERUM

T3

141.2

80 - 200

ng/dL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

5.1 - 14.1

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY

µg/dL

TSH (ULTRASENSITIVE)

0.270 - 4.200

µIU/mL

METHOD: ELECTROCHEMILUMINESCENCE, COMPETITIVE IMMUNOASSAY Interpretation(s)


> **End Of Report** Please visit www.srlworld.com for related Test Information for this accession

Dr. Swapnil Sirmukaddam

Consultant Pathologist

BHOOMI TOWER, 1ST FLOOR, HALL NO.1, PLOT NO.28 SECTOR 4, KHARGHAR NAVI MUMBAI, 410210 MAHARASHTRA, INDIA Tel: 9111591115,







Scan to View Report



Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN : 27AABCH5894D1ZG PAN NO : AABCH5894D





DEPARTMENT OF RADIOLOGY

Date: 26/Nov/2022

Name: Mrs. Yuvrani Battalwar

Age | Sex: 34 YEAR(S) | Female Order Station : FO-OPD

Bed Name:

UHID | Episode No : 5615822 | 59318/22/1501

Order No | Order Date: 1501/PN/OP/2211/126062 | 26-Nov-2022

Admitted On | Reporting Date: 26-Nov-2022 14:29:44

Order Doctor Name : Dr.SELF .

X-RAY-CHEST- PA

Findings:

Both lung fields are clear.

The cardiac shadow appears within normal limits.

Trachea and major bronchi appears normal.

Both costophrenic angles are well maintained.

Bony thorax are unremarkable.

DR. CHETAN KHADKE M.D. (Radiologist)

Mini Sea Shore Road, Sector 10-A, Vashi, Navi Mumbai - 400703.

Board Line: 022 - 39199222 | Fax: 022 - 39133220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199200 | Health Checkup: 022 - 39199300

www.fortishealthcare.com | vashi@fortishealthcare.com

CIN: U85100MH2005PTC 154823 GST IN : 27AABCH5894D1ZG PAN NO : AABCH5894D





(For Billing/Reports & Discharge Summary only)

DEPARTMENT OF RADIOLOGY

Date: 26/Nov/2022

Name: Mrs. Yuvrani Battalwar Age | Sex: 34 YEAR(S) | Female

Order Station : FO-OPD

Bed Name:

UHID | Episode No : 5615822 | 59318/22/1501 Order No | Order Date: 1501/PN/OP/2211/126062 | 26-Nov-2022 Admitted On | Reporting Date : 26-Nov-2022 15:12:54 Order Doctor Name : Dr.SELF.

US-WHOLE ABDOMEN

LIVER is normal in size (13.3 cm) and echogenicity. No IHBR dilatation. No focal lesion is seen in liver. Portal vein appears normal in caliber.

GALL BLADDER is minimally distended.

SPLEEN is normal in size (10.6 cm) and echogenicity.

BOTH KIDNEYS are normal in size and echogenicity. The central sinus complex is normal. No evidence of calculi/hydronephrosis.

Right kidney measures 9.0 x 4.1 cm.

Left kidney measures 11.0 x 5.6 cm.

PANCREAS: Head and body of pancreas is unremarkable. Rest of the pancreas is obscured.

URINARY BLADDER is normal in capacity and contour. Bladder wall is normal in thickness. No evidence of intravesical calculi.

UTERUS is normal in size, measuring 8.0 x 3.1 x 4.9 cm.

Endometrium measures 4.2 mm in thickness.

Both ovaries are normal.

Right ovary measures 2.9 x 1.2 cm.

Left ovary measures 3.7 x 1.4 cm. Dominant follicle is noted within, measuring 14 x 16 mm.

No evidence of ascites.

Impression:

No significant abnormality is detected.

DR. YOGESH PATHADE (MD Radio-diagnosis)

iranandani Heattneare Pvt. Ltd.

1ini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703
ioard Line: 022 - 39199222 | Fax: 022 - 39199220
imergency: 022 - 39199100 | Ambulance: 1255
ior Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

vww.fortishealthcare.com |

CIN : U85100MH2005PTC154823

3ST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





a M fortis remaind

	N	Date	26/11/203	22	
UHID	5615822	Sex	Female	Age	34
Name	Mrs.Yuvrani Battalwar				
OPD	Pap Smear				

Drug allergy: Sys illness:

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 | Fax: 022 - 39199220 Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





A M Fortis Nemant Eggen

UHID	5615822	Date	26/11/2022		
Name	Mrs. Yuvrani Battalwar	Sex	Female	Age	34
OPD	Opthal 14	Healtl	h Check U	p	

Drug allergy: Sys illness:

No ocular compaints

La: Alsquare

July Coll

VM(R->-0.50-0.75 × 60° fr. -> 616

t → -0.50×110° tryedres Prylishes 6/6/ M/1

(BB) X)rock

Hiranandani Healthcare Pvt. Ltd.

Mini Sea Shore Road, Sector 10 -A, Vashi, Navi Mumbai - 400703

Board Line: 022 - 39199222 Fax: 022 - 39199220

Emergency: 022 - 39199100 | Ambulance: 1255

For Appointment: 022 - 39199222 | Health Checkup: 022 - 39199300

www.fortishealthcare.com |

CIN: U85100MH2005PTC154823

GST IN: 27AABCH5894D1ZG | PAN NO: AABCH5894D





at M Fortis Section 1 7 7 1

	# (1 #022	Date	26/11/202	22	
UHID	5615822	Cov	Female	Age	34
Name Mrs. Yuvrani Battalwar	Sex				
OPD	Dental 12	Healt	h Check U	p	

Imparted

Drug allergy: Sys illness:

Carious

Popping in Pt

OP 6:

Adv Surgical semond F.
Adv Otal prophylaxis

Dilysha kaka.







PATIENT NAME: MRS. MRS.YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

34 Years AGE:

SEX: Female

ABHA NO:

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

		200 L	Biological Reference Interval	Units
Test Report Status	Final	Results	Biological Reference Interval	
LIEST REPORT STATUS	FIIIAI			

KIDNEY PANEL - 1


BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN

6 - 20

mg/dL

METHOD: UREASE - UV



CREATININE EGFR- EPI

CREATININE

0.69

34

116.72

0.60 - 1.10

mg/dL

METHOD: ALKALINE PICRATE KINETIC JAFFES

GLOMERULAR FILTRATION RATE (FEMALE)

years

AGE

Refer Interpretation Below

mL/min/1.73m2

METHOD: CALCULATED PARAMETER

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details











PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO:

REPORTED:

26/11/2022 13:39:00

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REFERRING DOCTOR: SELF


CLIENT NAME : FORTIS VASHI-CHC -SPLZD

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Units Biological Reference Interval Results **Test Report Status** Final



HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA



Scan to View Details



Scan to View Report









PATIENT NAME: MRS. MRS.YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO:

26/11/2022 13:39:00

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status Final

Biological Reference Interval Results

Units

METHOD: ISE INDIRECT

CHLORIDE, SERUM

103

98 - 107

mmol/L

METHOD: ISE INDIRECT

Interpretation(s)

PHYSICAL EXAMINATION, URINE

COLOR

PALE YELLOW

METHOD: PHYSICAL

APPEARANCE

SLIGHTLY HAZY

METHOD: VISUAL

CHEMICAL EXAMINATION, URINE

60

4.7 - 7.5

METHOD: REFLECTANCE SPECTROPHOTOMETRY- DOUBLE INDICATOR METHOD

SPECIFIC GRAVITY

<=1.005

1.003 - 1.035

METHOD: REFLECTANCE SPECTROPHOTOMETRY (APPARENT PKA CHANGE OF PRETREATED POLYELECTROLYTES IN RELATION TO IONIC CONCENTRATION)

PROTEIN

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY - PROTEIN-ERROR-OF-INDICATOR PRINCIPLE NOT DETECTED

GLUCOSE

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DOUBLE SEQUENTIAL ENZYME REACTION-GOD/POD

NOT DETECTED

KETONES

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ROTHERA'S PRINCIPLE

BLOOD

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, PEROXIDASE LIKE ACTIVITY OF HAEMOGLOBIN NOT DETECTED

BILIRUBIN

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, DIAZOTIZATION- COUPLING OF BILIRUBIN WITH DIAZOTIZED SALT

UROBILINOGEN

NORMAL

NORMAL

METHOD: REFLECTANCE SPECTROPHOTOMETRY (MODIFIED EHRLICH REACTION)

NOT DETECTED

NOT DETECTED

NITRITE

METHOD: REFLECTANCE SPECTROPHOTOMETRY, CONVERSION OF NITRATE TO NITRITE

LEUKOCYTE ESTERASE

NOT DETECTED

NOT DETECTED

METHOD: REFLECTANCE SPECTROPHOTOMETRY, ESTERASE HYDROLYSIS ACTIVITY

MICROSCOPIC EXAMINATION, URINE

RED BLOOD CELLS

NOT DETECTED

NOT DETECTED

/HPF

METHOD: MICROSCOPIC EXAMINATION

PUS CELL (WBC'S)

3-5

0-5

/HPF

METHOD: MICROSCOPIC EXAMINATION

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,

Scan to View Details











PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID . LID: 5615822

ACCESSION NO:

0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO:

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

URINARY MICROSCOPIC EXAMINATION DONE ON URINARY

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status <u>Final</u>	Results	Biological Reference	Interval Units
EPITHELIAL CELLS	20-30	0-5	/HPF
METHOD: MICROSCOPIC EXAMINATION CASTS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION CRYSTALS	NOT DETECTED		
METHOD: MICROSCOPIC EXAMINATION BACTERIA	DETECTED (FEW)	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION YEAST	NOT DETECTED	NOT DETECTED	
METHOD: MICROSCOPIC EXAMINATION			

CENTRIFUGED SEDIMENT

Interpretation(s)

REMARKS

Interpretation(s)
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.

CREATININE EGFR- EPI-

GFR— Glomerular filtration rate (GFR) is a measure of the function of the kidneys. The GFR is a calculation based on a serum creatinine test. Creatinine is a muscle waste product that is filtered from the blood by the kidneys and excreted into urine at a relatively steady rate. When kidney function decreases, less creatinine is excreted and concentrations increase in the blood. With the creatinine test, a reasonable estimate of the actual GFR can be determined. A GFR of 60 or higher is in the normal range.

A GFR below 60 may mean kidney disease.

A GFR of 15 or lower may mean kidney failure.

A GFR of 15 or lower may mean kidney failure.

Estimated GFR (eGFR) is the preferred method for identifying people with chronic kidney disease (CKD). In adults, eGFR calculated using the Modification of Diet in Renal Disease (MDRD) Study equation provides a more clinically useful measure of kidney function than serum creatinine alone.

The CKD-EPI creatinine equation is based on the same four variables as the MDRD Study equation, but uses a 2-slope spline to model the relationship between estimated GFR and serum creatinine, and a different relationship for age, sex and race. The equation was reported to perform better and with less bias than the MDRD Study equation,

especially in patients with higher GFR. This results in reduced misclassification of CKD.

The CKD-EPI creatinine equation has not been validated in children & will only be reported for patients = 18 years of age. For pediatric and childrens, Schwartz Pediatric Bedside eGFR (2009) formulae is used. This revised "bedside" pediatric eGFR requires only serum creatinine and height. URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake, Prolonged Fasting, Rapid weight loss), Gout, Lesch nyhan syndrome, Type 2 DM, Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. ALBUMIN, SERUM-

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

SRL Ltd

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MRS. MRS.YUVRANI BATTALWAR

PATIENT ID : FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005846 AGE: 34 Years

SEX: Female

ABHA NO:

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval


	HAEMATOLO			
ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD				
E.S.R	06		0 - 20	mm at 1 hr
METHOD: WESTERGREN METHOD				
CBC-5, EDTA WHOLE BLOOD				
BLOOD COUNTS, EDTA WHOLE BLOOD				2
HEMOGLOBIN (HB)	13.7		12.0 - 15.0	g/dL
METHOD: SPECTROPHOTOMETRY				
RED BLOOD CELL (RBC) COUNT	5.07	High	3.8 - 4.8	mil/μL
METHOD: ELECTRICAL IMPEDANCE		4		
WHITE BLOOD CELL (WBC) COUNT	8.47		4.0 - 10.0	thou/µL
METHOD: DOUBLE HYDRODYNAMIC SEQUENTIAL SYSTEM(DH	SS)CYTOMETRY			
PLATELET COUNT	332		150 - 410	thou/µL
METHOD: ELECTRICAL IMPEDANCE	â			
RBC AND PLATELET INDICES				
HEMATOCRIT (PCV)	40.5		36 - 46	%
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	79.8	Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	27.0		27.0 - 32.0	pg
METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER	33.8		31.5 - 34.5	g/dL
RED CELL DISTRIBUTION WIDTH (RDW)	13.3		11.6 - 14.0	%
METHOD: CALCULATED PARAMETER				
MENTZER INDEX	15.7	¥		
MEAN PLATELET VOLUME (MPV)	9.1	;	6.8 - 10.9	fL
METHOD: CALCULATED PARAMETER				
WBC DIFFERENTIAL COUNT				
NEUTROPHILS	69		40 - 80	%
METHOD: FLOW CYTOMETRY	77			
LYMPHOCYTES	18	Low	20 - 40	%
METHOD: FLOW CYTOMETRY				

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MRS. MRS.YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO :

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD

BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

BILLNO-150122OPCRUS	59905				
Test Report Status	<u>Final</u>	Results		Biological Reference	Interval
MONOCYTES		. 6		2 - 10	%
METHOD : FLOW CYTOMETRY	κ	124			
EOSINOPHILS		7	High	1 - 6	%
METHOD : FLOW CYTOMETRY	<i>(</i>				
BASOPHILS		00		0 - 2	%
METHOD : FLOW CYTOMETRY	r				
ABSOLUTE NEUTROPHI	L COUNT	5.84		2.0 - 7.0	thou/µL
METHOD: CALCULATED PAR	AMETER				
ABSOLUTE LYMPHOCYT	E COUNT	1.52		1.0 - 3.0	thou/µL
METHOD : CALCULATED PAR	AMETER				
ABSOLUTE MONOCYTE	COUNT	0.51		0.2 - 1.0	thou/µL
METHOD : CALCULATED PAR	AMETER				
ABSOLUTE EOSINOPHI	IL COUNT	0.59	High	0.02 - 0.50	thou/µL
METHOD : CALCULATED PAR	AMETER				
ABSOLUTE BASOPHIL	COUNT	0	Low	0.02 - 0.10	thou/µL
METHOD: CALCULATED PAR	RAMETER				
NEUTROPHIL LYMPHOO	CYTE RATIO (NLR)	3.8			
METHOD : CALCULATED PAR	RAMETER	ű.			
MORPHOLOGY					
RBC		PREDOMINANTI	Y NORMOC	YTIC NORMOCHROMIC	
METHOD : MICROSCOPIC E	XAMINATION				
WBC		NORMAL MORP	HOLOGY		
METHOD : MICROSCOPIC E	XAMINATION			2	
PLATELETS		ADEQUATE			

Interpretation(s)

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION:
Erythrocyte Sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

METHOD: MICROSCOPIC EXAMINATION

LIMITATIONS

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA







Scan to View Report









PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

SEX: Female 34 Years

ABHA NO:

ACCESSION NO:

0022VK005846 DRAWN: 26/11/2022 11:20:00

AGE: RECEIVED: 26/11/2022 11:20:16 REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189 CORP-OPD BILLNO-1501220PCR059905 BILLNO-150122OPCR059905

Final Test Report Status

Results

Biological Reference Interval

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia
False ecreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine, False Decreased: Poikilocytosis, Counts)

REFERENCE:

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis; 10th edition.

RBC AND PLATELET INDICES—Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13)

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of fron deficiency anaemia(>13) from Beta thalassaemia trait (<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3,3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504. This ratio element is a calculated parameter and out of NABL scope.

This ratio element is a calculated parameter and out of NABL scope.

IMMUNOHAEMATOLOGY

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP

TYPE B

METHOD: TUBE AGGLUTINATION

RH TYPE

METHOD: TUBE AGGLUTINATION

POSITIVE

ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in Interpretation(s)
ABO GROUP & RH TYPE, EDTA WHOLE BLOODplasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

availability of the severse of 0	uping methods.		
The test is performed by both forward as well as reverse gro	BIO CHEMISTRY		
LIVER FUNCTION PROFILE, SERUM	0.61	0.2 - 1.0	mg/dL
BILIRUBIN, TOTAL	0.01	0.0 - 0.2	mg/dL
METHOD: JENDRASSIK AND GROFF BILIRUBIN, DIRECT	0.11	0.0 - 0.2	200
METHOD : JENDRASSIK AND GROFF	0.50	0.1 - 1.0	mg/dL
BILIRUBIN, INDIRECT METHOD: CALCULATED PARAMETER	7.0	6.4 - 8.2	g/dL
TOTAL PROTEIN	7.0	3.4 - 5.0	g/dL
METHOD: BIURET ALBUMIN	3.6	3.4 - 3.0	Page 7 Of 15
		(E) (2.75) (10% (E)	1490 /

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD,

SECTOR 10,

NAVI MUMBAI, 400703 MAHARASHTRA, INDIA



Scan to View Details



Scan to View Report









PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005846 AGE: 34 Years

SEX: Female

ABHA NO:

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD


BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status	Final	Results		Biological Reference Interv	al
			8		
METHOD : BCP DYE BINDIN	G				HIMI
GLOBULIN		3.4		2.0 - 4.1	g/dL
METHOD: CALCULATED PA	RAMETER	590 BL 1527			DATIO
ALBUMIN/GLOBULIN I	РАПО	1.1		1.0 - 2.1	RATIO
METHOD: CALCULATED PA		1904		15 27	U/L
ASPARTATE AMINOTR METHOD: UV WITH P5P	ANSFERASE (AST/SGOT)	18		15 - 37	U/L
ALANINE AMINOTRAN METHOD: UV WITH P5P	SFERASE (ALT/SGPT)	40	High	< 34.0	U/L
ALKALINE PHOSPHATA	ASE	54		30 - 120	U/L
GAMMA GLUTAMYL TR	ANSFERASE (GGT) NYLCARBOXY 4NITROANILIDE	23		5 - 55	U/L
LACTATE DEHYDROGE		152		100 - 190	U/L
METHOD : LACTATE -PYRU	/ATE				
LIPID PROFILE, SE	RUM				
CHOLESTEROL, TOTAL	_	164		< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD: ENZYMATIC/CO	LORIMETRIC, CHOLESTEROL OXIDASE,	ESTERASE, PEROXIDASE			
TRIGLYCERIDES		40		< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD: ENZYMATIC AS:	5AY .				70
HDL CHOLESTEROL		55		< 40 Low >/=60 High	mg/dL
METHOD : DIRECT MEASU		i an in			
LDL CHOLESTEROL, I	DIRECT	96		< 100 Optimal 100 - 129 Near or above opti 130 - 159 Borderline High 160 - 189 High >/= 190 Very High	mg/dL mal
METHOD: DIRECT MEASU	RE WITHOUT SAMPLE PRETREATMENT	10000000		820 05 \$750 94 94187 ROBERTS	551.004394
NON HDL CHOLESTE	ROL	109		Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219 Very high: > or = 220	mg/dL
A Commission of the Commission	and the state of t				

METHOD: CALCULATED PARAMETER

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,





Scan to View Report

Patient Ref. No. 22000000811279

Page 8 Of 15







PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005846 AGE: 34 Years

SEX: Female

ABHA NO:

26/11/2022 13:39:00

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF


CLINICAL INFORMATION:

CORP-OPD


BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

UID:5615822 REQNO-1326189

Test Report Status <u>Final</u>	Results		Biological Reference	e Interval
CHOL/HDL RATIO	3.0	Low	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Ris 7.1 - 11.0 Moderate I > 11.0 High Risk	
METHOD: CALCULATED PARAMETER				
LDL/HDL RATIO	1.8		0.5 - 3.0 Desirable/Lo 3.1 - 6.0 Borderline/N >6.0 High Risk	
METHOD: CALCULATED PARAMETER			Mr.	
VERY LOW DENSITY LIPOPROTEIN METHOD: CALCULATED PARAMETER	8.0		= 30.0</td <td>mg/dL</td>	mg/dL



SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,















PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO: 0022VK005846

AGE: 34 Years SEX: Female

ABHA NO:

26/11/2022 13:39:00

RECEIVED: 26/11/2022 11:20:16

REPORTED:

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

DRAWN: 26/11/2022 11:20:00


UID:5615822 REONO-1326189 CORP-OPD


BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status Final

Results

Biological Reference Interval





SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report

Page 10 Of 15 Patient Ref. No. 22000000811279







PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID:

FH.5615822

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

AGE: 34 Years

SEX: Female

ABHA NO:

DRAWN: 26/11/2022 11:20:00

RECEIVED: 26/11/2022 11:20:16

REPORTED: 26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REONO-1326189


CORP-OPD BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval



GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR)

METHOD: HEXOKINASE

107

High 74 - 99

mg/dL

SRL Ltd HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details











PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

PATIENT ID : FH.5615822

CLIENT PATIENT ID: UID:5615822

DRAWN: 26/11/2022 11:20:00

ACCESSION NO: 0022VK005846 AGE: 34 Years

SEX: Female

ABHA NO:

RECEIVED: 26/11/2022 11:20:16

REPORTED:

26/11/2022 13:39:00

CLIENT NAME : FORTIS VASHI-CHC -SPLZD

REFERRING DOCTOR: SELF

CLINICAL INFORMATION:

UID:5615822 REQNO-1326189


CORP-OPD BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval



GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C

5.5

Non-diabetic: < 5.7

Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5ADA Target: 7.0

Action suggested: > 8.0

METHOD: HB VARIANT (HPLC)

METHOD: CALCULATED PARAMETER

ESTIMATED AVERAGE GLUCOSE(EAG)

111.2

< 116.0

mg/dL

%

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703 MAHARASHTRA, INDIA

Tel: 022-39199222,022-49723322,



Scan to View Details











PATIENT NAME: MRS. MRS. YUVRANI BATTALWAR

FH.5615822 PATIENT ID:

CLIENT PATIENT ID: UID:5615822

ACCESSION NO:

0022VK005846

34 Years AGE:

SEX: Female

ABHA NO:

26/11/2022 13:39:00

REPORTED :

RECEIVED: 26/11/2022 11:20:16

DRAWN: 26/11/2022 11:20:00

REFERRING DOCTOR: SELF

CLIENT NAME : FORTIS VASHI-CHC -SPLZD CLINICAL INFORMATION:

UID:5615822 REQNO-1326189

CORP-OPD


BILLNO-1501220PCR059905 BILLNO-1501220PCR059905

Test Report Status

Final

Results

Biological Reference Interval



LIVER FUNCTION PROFILE
Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give
yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg,
yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased more than unconjugated
obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (direct) bilirubin in Viral hepatitis, Drug reactions, alcoholic liver disease Conjugated (dire

attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver,liver cancer,kidney failure,hemolytic anemia, pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood. In anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of a diagnostic evaluation of is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction of a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction.

nepatocellular injury, to determine liver nealth.AST levels increase during acute nepatos, sometimes due to a viral infection, iscnemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction in the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction. ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction. It is a protein found in almost all body tissues mainly in the liver, kidney and pancreas in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas in a seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source in a seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source in the liver. Serum GGT activity. Can be found in diseases of the liver, billiant and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source in the liver. Serum GGT activity. Can be found in diseases of the liver of the billiant and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Chronic inflammation or in

HIRANANDANI HOSPITAL-VASHI, MINI SEASHORE ROAD, SECTOR 10, NAVI MUMBAI, 400703

MAHARASHTRA, INDIA Tel: 022-39199222,022-49723322,



Scan to View Details



Scan to View Report

